Quantcast

Latest Healthcare-associated pneumonia Stories

2008-10-26 12:00:10

REINACH, Switzerland, Oct. 26 /PRNewswire-FirstCall/ -- Arpida today presented the combined results from two pivotal Phase III clinical trials at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, DC. In these studies, intravenous iclaprim, a novel antibiotic, showed high clinical cure rates which were similar to those of the comparator drug, linezolid, in the treatment of...

2008-08-21 09:01:14

Arpida has announced that the European Medicines Agency has accepted for review its marketing authorization application for intravenous iclaprim. Arpida is seeking approval of intravenous iclaprim in the EU for the treatment of complicated skin and soft tissue infections (cSSTI). Iclaprim is a hospital antibiotic drug candidate with potent bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) and an extended range of important pathogens. The iclaprim marketing...

2008-08-21 06:01:02

REINACH, Switzerland, August 21 /PRNewswire-FirstCall/ -- Arpida Ltd. today announced that the European Medicines Agency (EMEA) has accepted for review its Marketing Authorisation Application (MAA) for intravenous iclaprim. Arpida is seeking approval of intravenous iclaprim in the European Union for the treatment of complicated Skin and Soft Tissue Infections (cSSTI). Iclaprim is a hospital antibiotic drug candidate with potent bactericidal (killing) activity against MRSA and an extended...

2008-07-30 06:00:54

Arpida has submitted a marketing authorization application for intravenous iclaprim for the treatment of complicated skin and soft tissue infections to the European Medicines Agency. The iclaprim marketing authorization application (MAA) contains data from 15 clinical studies, including two well-controlled multinational pivotal Phase III trials (Assist-1 and Assist -2, in which approximately 1,000 patients were treated), the company said. Patients enrolled in the Phase III trials exhibited...

2008-06-26 12:03:21

Californians hospitalized with community-acquired pneumonia (CAP) could more than double their chances of survival if they are treated at one of the top-rated hospitals, according to a newly released report from the Office of Statewide Health Planning and Development (OSHPD), "Community Acquired Pneumonia: Hospital Outcomes in California, 2003-2005." In this third report on CAP quality of care, the report provides statistical analysis on the outcomes of 208,000 adult pneumonia patients...

e6d4cb1c264fa956a2a5fb915d5969ca1
2008-03-19 12:05:13

Preliminary research from the Centers for Disease Control and Prevention (CDC) suggests that community acquired pneumonia (CAP) caused by the Staphylococcus aureus bacterium may be more common than originally suspected, including that caused by antibiotic resistant strains. Researchers report their findings today (March 19) at the 2008 International Conference on Emerging Infectious Diseases in Atlanta, Georgia."Over the last few years we have been receiving reports of a severe CAP caused by...

2006-03-15 18:05:00

WASHINGTON (Reuters) - A pneumonia vaccine seems to save the lives of older adults who become so ill that they are hospitalized, even if does not prevent them from getting pneumonia, researchers said on Wednesday. A study in several U.S. states showed that hospital patients who had been vaccinated were 40 to 70 percent less likely to die than unvaccinated patients, or those who could not remember whether they had been vaccinated. The vaccinated patients had a lower risk of respiratory...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'